JP2012504604A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504604A5
JP2012504604A5 JP2011530048A JP2011530048A JP2012504604A5 JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5 JP 2011530048 A JP2011530048 A JP 2011530048A JP 2011530048 A JP2011530048 A JP 2011530048A JP 2012504604 A5 JP2012504604 A5 JP 2012504604A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
con
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011530048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/005407 external-priority patent/WO2010039237A1/en
Publication of JP2012504604A publication Critical patent/JP2012504604A/ja
Publication of JP2012504604A5 publication Critical patent/JP2012504604A5/ja
Pending legal-status Critical Current

Links

JP2011530048A 2008-10-01 2009-10-01 炎症および免疫関連使用のための化合物 Pending JP2012504604A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19483108P 2008-10-01 2008-10-01
US61/194,831 2008-10-01
PCT/US2009/005407 WO2010039237A1 (en) 2008-10-01 2009-10-01 Compounds for inflammation and immune-related uses

Publications (2)

Publication Number Publication Date
JP2012504604A JP2012504604A (ja) 2012-02-23
JP2012504604A5 true JP2012504604A5 (enExample) 2012-11-22

Family

ID=41263687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530048A Pending JP2012504604A (ja) 2008-10-01 2009-10-01 炎症および免疫関連使用のための化合物

Country Status (7)

Country Link
US (3) US8314130B2 (enExample)
EP (1) EP2350064A1 (enExample)
JP (1) JP2012504604A (enExample)
AU (1) AU2009300317A1 (enExample)
CA (1) CA2739322A1 (enExample)
TW (1) TW201026693A (enExample)
WO (1) WO2010039237A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515788A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
PL2563776T3 (pl) 2010-04-27 2017-01-31 Calcimedica Inc Związki, które modulują wewnątrzkomórkowy wapń
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
CA2825684C (en) * 2011-01-28 2021-11-23 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
JP5985611B2 (ja) * 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EA036265B1 (ru) 2015-02-27 2020-10-20 Кальцимедика, Инк. Лечение панкреатита
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2019054430A1 (ja) * 2017-09-14 2019-03-21 第一三共株式会社 芳香族複素環を有するアミド化合物
MX2021003094A (es) 2018-09-14 2021-05-12 Rhizen Pharmaceuticals A G Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN118084860A (zh) * 2024-02-06 2024-05-28 中国药科大学 芳酰胺类化合物及其药物组合物和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US7232838B2 (en) * 2001-08-13 2007-06-19 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
CA2593550A1 (en) * 2005-01-07 2006-08-10 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
TWI444187B (zh) * 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
CA2639913A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
ES2440267T3 (es) * 2007-08-01 2014-01-28 Synta Pharmaceuticals Corporation Compuestos de heterociclo-arilo para la inflamación y usos inmunorrelacionados
WO2009017819A1 (en) * 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses

Similar Documents

Publication Publication Date Title
JP2012504604A5 (enExample)
JP2010509342A5 (enExample)
CA2669695A1 (en) Tetrahydropyridinyl compounds for inflammation and immune-related uses
JP2012504603A5 (enExample)
JP2010535218A5 (enExample)
JP2011525915A5 (enExample)
CN107592864B (zh) 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
AU2008287799B2 (en) Method for producing pyripyropene derivative and production intermediate thereof
JP2013525433A5 (enExample)
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
JP2011016800A5 (enExample)
JP2010535214A5 (enExample)
JP2015502387A5 (enExample)
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2017218580A1 (en) Synthetic methods for the preparation of nicotinamide riboside and related compounds
CA2796872A1 (en) Novel synthesis for thiazolidinedione compounds
JP2018515531A5 (enExample)
JP2009530283A5 (enExample)
JP2013533883A5 (enExample)
WO2011005295A8 (en) Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
US20190202834A1 (en) Baricitinib intermediate, method for forming baricitinib intermediate, and method for preparing baricitinib or pharmaceutically acceptable salt thereof
JP2018502083A5 (enExample)
JP2008508199A (ja) マスキングされたイソシアネート基を有するオルガノ珪素化合物
EP3344634B1 (de) (meth)acrylatgruppen aufweisende organosiliciumverbindungen und ein verfahren zu ihrer herstellung
JP2013510900A5 (enExample)